A Phase 3 interventional study of Avelumab and Lorlatanib in Advanced Malignancies, NSCLC and Ovarian Cancer, sponsored by Pfizer. Active, not recruiting at 71 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Ovarian Neoplasms by Pfizer — 1 open to participants now, 4 under way, 1 of them phase 3. Ovarian Neoplasms · Pfizer.
Among the 38 studies in Ovarian Neoplasms by Pfizer, this one is the 17th largest by enrollment, is one of 6 that started in 2021, is one of 5 in phase 3, and was the 27th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →1 of the 38 studies in Ovarian Neoplasms by Pfizer is open now, in 7 countries. Recruiting first, the newest first:
Seagen, a wholly owned subsidiary of Pfizer · Sites in United States, France, Korea, Republic of and 4 more countries
Ages 18+
By country, each count listing its studies:
Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 11 · Phase 3 5
First in 2003; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 77 is above the median of 54 across 2,555 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 52 across the 38 interventional studies. Of the 32 that completed or were terminated, 18 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
3 of the studies in Ovarian Neoplasms by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05059522Phase 3PfizerContinued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | 2026-12-31 |
| NCT04553133PfizerPF-07104091 as a Single Agent and in Combination Therapy | 2026-12-31 |
| NCT04389632Seagen, a wholly owned subsidiary of PfizerA Study of Sigvotatug Vedotin in Advanced Solid Tumors | 2027-06-16 |
Add all 3 to your calendar (.ics) → With an account.
Among the 38 studies in Ovarian Neoplasms by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.
B9991046 is a master protocol that will consist of sub-studies from the following parent studies:
B9991001 - NCT02603432 B9991003 - NCT02684006 B9991004 - NCT02554812 B9991005 - NCT02584634 B9991009 - NCT02580058 B9991023 - NCT03317496 B9991025 - NCT03330405 B9991027 - NCT03472560 B9991032 - NCT03565991
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Avelumab monotherapy as specified by sub-study protocol B9991001C
Drug: Avelumab
Avelumab in combination with CMP 001, Utomilumab or PF04518600 as specified by sub-study protocol B9991004C
Drug: Avelumab · Drug: CMP 001 · Drug: Utomilumab · Drug: PF04518600
Avelumab in combination with Loratanib as specified by sub-study protocol B9991005C
Drug: Avelumab · Drug: Lorlatanib
Avelumab monotherapy as specified by sub-study protocol B9991009C
Drug: Avelumab
Avelumab monotherapy or in combination with Pemetrexed as specified by sub-study protocol B9991023C
Drug: Avelumab · Drug: Pemetrexed
Avelumab in combination with Talazoparib as specified by sub-study B9991025C.
Drug: Avelumab · Drug: Talazoparib
Avelumab in combination with Axitinib as specified by sub-study B9991027C.
Drug: Avelumab · Drug: Axitinib
Avelumab in combination with Talazoparib as specified by sub-study B9991032C.
Drug: Avelumab · Drug: Talazoparib
Avelumab in combination with Axitinib as specified by sub-study protocol B9991003C
Drug: Avelumab · Drug: Axitinib
oral
oral
oral
IV (intravenous) infusion
oral
IT (intratumoral) or SC (subcutaneous)
IV infusion
IV infusion
Number of participants with adverse events leading to permanent discontinuation of study intervention
Time frame: Baseline up to approximately 5 years
Number serious adverse events reported for all participants
Time frame: Baseline up to approximately 5 years
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Started Sep 2021 (actual). Primary completion is estimated for Dec 2026, 63 months after the start.
Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 63 months is above that.
Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avelumab